Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA

27.2.2026 00:00:00 EET | Business Wire | Press release

Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the future of quality and patient safety in cancer care.

Building on its legacy as a peer-driven forum with practical applications, QADS 2026 features sessions delivered by 24 speakers spanning:

Future Directions in Machine and Patient QA and In-vivo Dosimetry
Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) QA
Safety and Guideline-driven Tool Selection
Emerging Technologies, including Theranostics, AI and Automation

Reinforcing its role as a launch point for clinically grounded innovation, QADS 2026 will serve as the introduction of Daily QA™ 4 Pro, Sun Nuclear’s latest advancement for daily machine QA. Attendees will receive an early look at how Daily QA 4 Pro combines dosimetry and imaging/positioning checks into one indexed, imageable device that supports faster setup, fewer room entries and more consistent workflows.

David Barbee, Ph.D., DABR, of NYU Langone Health will deliver a keynote presentation exploring early clinical experience with the Daily QA 4 Pro device. The session examines the evolving landscape of daily machine quality assurance, drawing on comparative measurement data from independent QA tools and machine performance checks to highlight how diverse data sources can be reviewed, interpreted and meaningfully integrated into clinical QA workflows. Through real‑world examples, the discussion will address efficiencies, limitations of existing approaches, and emerging opportunities to improve data visibility, trend analysis and workflow understanding—setting the stage for informed dialogue on the future direction of machine QA.

In addition, QADS will feature demonstrations of an AI-powered plan quality enablement solution, Plan AI™, which recently received CE mark, making it available for sale in Europe. Attendees can explore how Plan AI simultaneously accelerates radiation planning speeds and elevates plan quality and consistency. These demonstrations complement the symposium’s technical sessions by offering hands-on exposure to emerging capabilities.

“As clinical quality management demands continue to grow, forums like QADS play a critical role in bringing the community together to share experiences, evaluate new approaches, and focus on what delivers real value in practice,” said Luis Rivera, Executive Vice President for Mirion Medical, and President for Sun Nuclear. “QADS reflects our commitment to supporting physicists and clinical care teams with solutions and conversations that are grounded in clinical reality and focused on improving quality and efficiency.”

To learn more about QADS, visit qasymposium.com.

About Mirion

Mirion is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group is committed to powering advancements in nuclear energy through proven radiation safety technologies and expertise. The Mirion Medical group is focused on improving quality in cancer care through its broad range of solutions that enhance delivery and ensure safety across the medical landscape. Headquartered in Atlanta (GA – USA), Mirion employs approximately 3,200 people and operates in 12 countries.

Varian Medical Systems^® is a registered trademark, and Varian™ and Machine Performance Checks are trademarks, of Varian Medical Systems, Inc. Sun Nuclear is not affiliated with or sponsored by Varian Medical Systems, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226537656/en/

Contacts

For media inquiries:
Erin Schesny
media@mirion.com

For investor inquiries:
Eric Linn
ir@mirion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release

Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 16:00:00 EEST | Press release

Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 15:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duration while maintaining flexible, up to once-monthly dosing for patients (every three or four weeks for PID). The TAK-881-3001 clinical trial ev

Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 13:00:00 EEST | Press release

Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles the range and resolution of its lidar over the prior generation, adds native-color sensing, and is designed for functional safety. Based on patented Ouster Silicon with embedded Fujifilm color science, the L4 chip results in exquisite color data and hardware-enabled HDR. It boasts 42.9 GMACs of p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom